APOA1 and autoimmune pancreatitis: In a prevention study, the protective effect of the recurrent administration of Ins-ApoAI and/or glucose was assayed in AIP mice to mimic the prophylactic therapy some patients receive when beginning with prodromal symptoms associated with an acute attack (Figure 4).